June 14, 2016 – FDA strengthens existing warnings about an increased risk of acute kidney injury with dapagliflozin (Xigduo XR, Farxiga) and canagliflozin (Invokana, Invokamet).
June 14, 2016 – FDA strengthens existing warnings about an increased risk of acute kidney injury with dapagliflozin (Xigduo XR, Farxiga) and canagliflozin (Invokana, Invokamet).